RxDoctor Payments DataLook up a doctor →

Laura Bunch, MD

Medical Oncology · Irondale, ALNPI 1295773125

Payments from drug & device makers

$10,125in general payments, 2019–2025

Across 513 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novartis$840
  • Daiichi Sankyo Inc.$813
  • Johnson & Johnson$590
  • E.r. Squibb & Sons, L.L.C.$561
  • Myriad Genetic Laboratories, Inc.$418
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca54$1,050
Novartis44$840
Daiichi Sankyo Inc.40$813
Johnson & Johnson26$590
E.r. Squibb & Sons, L.L.C.37$561
Myriad Genetic Laboratories, Inc.11$418
Merck21$394
Stemline Therapeutics Inc.17$345
AbbVie16$295
Pfizer16$255
Seagen Inc.8$227
Eisai Inc.13$223
Pharmacyclics LLC, An Abbvie Company12$219
Amgen12$210
Bristol Myers Squibb11$194
Pharmaessentia USA Corporation6$182
Ipsen Biopharmaceuticals, Inc9$178
Incyte Corporation9$176
Bayer9$176
Takeda Pharmaceuticals U.S.A., Inc.7$176
Astellas Pharma US Inc7$136
Gilead(2 entities)7$135
Genentech USA, Inc.7$135
Morphosys, US Inc.7$133
Sanofi6$131
AVEO Pharmaceuticals, Inc.7$131
Foundation Medicine, Inc.7$115
Sobi, Inc3$108
Array Biopharma Inc5$107
Boehringer Ingelheim4$107
Exelixis Inc.5$87
Beone Medicines USA, Inc.4$82
Lilly USA, LLC4$74
GSK3$61
Acrotech Biopharma Inc.3$54
Puma Biotechnology, Inc.3$53
Beigene USA, Inc.3$51
Sun Pharmaceutical Industries Inc.2$49
ADC Therapeutics America, Inc.3$49
Pharmacosmos Therapeutics Inc.2$47
Global Blood Therapeutics, Inc.3$47
Rigel Pharmaceuticals, Inc.3$46
Immunocore Limited1$44
Fennec Pharmaceuticals, Inc.2$41
Regeneron Healthcare Solutions, Inc.3$41
Deciphera Pharmaceuticals Inc.2$41
Genmab U.S., Inc.2$40
Blueprint Medicines Corporation2$40
Jazz Pharmaceuticals Inc.2$38
Progenics Pharmaceuticals, Inc.2$37
Sumitomo Pharma America, Inc.2$35
EMD Serono, Inc.2$32
Taiho Oncology, Inc.2$31
Adaptive Biotechnologies Corporation2$28
Recordati_rare_diseases_inc.1$24
Agios Pharmaceuticals, Inc.1$21
Novocure Inc.1$20
G1 Therapeutics, Inc.1$19
Dova Pharmaceuticals1$18
Servier Pharmaceuticals LLC1$17

How this compares

$10,125 in reported general payments places this provider in the 45th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama →

Medicare billing

Part B allowed, 2024
$802,911
Medicare patients
288
Services billed
59,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Irondale

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →